GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.

As Neurelis awaits an FDA decision on its flagship drug, the company has launched its first seizure awareness campaign.

GSK has the strictest sales pay rules in the industry, but it's loosening up. It will now allow specialty salespeople to take home bigger paychecks.

Sarepta Therapeutics’ DMD therapy Exondys has already been knocked for its skimpy clinical data. Now a price watchdog says it’s also too expensive.

When it comes to Invokana sales, J&J needs a way to stop the bleeding. And it just took a step closer to a new approval that could do just that.

Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.

Novartis last year said its forthcoming SMA gene therapy could be cost-effective at up to $5 million. Now, its CEO says the price will be "far lower."

Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years.

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.